Key Drivers
- Margin Strength
- Cash Burn
- Rising Leverage
AIAI Summary
BCRX has shifted from a speculative pipeline story to a real but more demanding commercial one, with ORLADEYO driving solid revenue growth and high gross margins, but investors should focus on whether management can convert that growth into durable cash flow while managing rising debt, dilution, and partner-dependent upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Cash Burn
- •Rising Leverage
BCRX still has strong gross economics and adequate liquidity, but the Q1 2026 loss, negative cash flow, and rising leverage materially weaken the investment case. ക ക
Price Behavior
Key Price Behavior Insights:
- •Range-bound support
- •Failed breakout
- •Weakening momentum
BCRX spent the last month trading sideways with support at $8.58–$8.80, but the failed push near $9.57–$9.60 and drop back to $9.02 suggest momentum is weakening unless it reclaims $9.60.
Sharp pullback from the $9.60 area to $9.02 on 2026-05-15
Sentiment & News
Key News Insights:
- •ORLADEYO Momentum
- •Navenibart Licensing
- •Investor Visibility
BioCryst's early-May updates pointed to stronger ORLADEYO sales, a smaller-than-expected quarterly loss, and continued progress in its hereditary angioedema strategy.
The stronger revenue trend and ongoing HAE execution should support a more positive near-term outlook for BioCryst's shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings